Ann J. Barbier
Net worth: 55 331 $ as of 2026-06-29
Net worth: 55 331 $ as of 2026-06-29
Ann J.
Barbier currently works at Vicore Pharma Holding AB, as Director from 2024.
Dr. Barbier also formerly worked at Shire Human Genetic Therapies, Inc., as Senior Director-Medical from 2007 to 2011, Pieris Pharmaceuticals, Inc., as Independent Director from 2018 to 2024, Agios Pharmaceuticals, Inc., as Vice President-Clinical Development from 2015 to 2017, Translate Bio, Inc., as Chief Medical Officer from 2017 to 2021, Shire Pharmaceuticals, Inc., as Global Lead-Clinical Development from 2014 to 2015, and CAMP4 Therapeutics Corp., as Chief Medical Officer from 2022 to 2023.
Dr. Barbier received her doctorate degree in 1985 from Ghent University and graduate degree in 1995 from Université Libre de Bruxelles.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2025-12-30 | 42,500 ( 0.02% ) | 55 331 $ | 2026-06-29 |
| Companies | Position | Start |
|---|---|---|
| VICORE PHARMA HOLDING AB | Director/Board Member | 2024-05-06 |
| Companies | Position | End |
|---|---|---|
| PIERIS PHARMACEUTICALS | Director/Board Member | 2024-12-12 |
| CAMP4 THERAPEUTICS CORPORATION | Chief Tech/Sci/R&D Officer | 2023-09-30 |
| TRANSLATE BIO, INC. | Chief Tech/Sci/R&D Officer | 2021-09-13 |
| AGIOS PHARMACEUTICALS, INC. | Corporate Officer/Principal | 2017-09-30 |
Shire Pharmaceuticals, Inc.
Shire Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Chief Tech/Sci/R&D Officer | 2015-04-30 |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 9 |
|---|---|
Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops therapeutics | Health Technology |
Translate Bio, Inc.
Translate Bio, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage mRNA therapeutics company that develops transformative medicines to treat diseases caused by protein | Health Technology |
Ghent University
Ghent University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Université Libre de Bruxelles
Université Libre de Bruxelles Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Shire Human Genetic Therapies, Inc.
Shire Human Genetic Therapies, Inc. Medical SpecialtiesHealth Technology Develops human genetic therapies | Health Technology |
Shire Pharmaceuticals, Inc.
Shire Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Vicore Pharma Holding AB
Vicore Pharma Holding AB Pharmaceuticals: MajorHealth Technology Engages in research and development of drugs for lung diseases | Health Technology |
Pieris Pharmaceuticals, Inc.
Pieris Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops and markets an anticalin-brand protein technology | Health Technology |
Camp4 Therapeutics Corp.
Camp4 Therapeutics Corp. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that engages in the development of regulatory RNA-based therapeutics | Health Technology |
Select your edition
All financial news and data tailored to specific country editions